Dan Comaniciu / Shutterstock.com
Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC.
C5’s Life Sciences IP Summit returns for its third year, offering a comprehensive programme that is bursting with variety, topical relevance and focused discussion on the issues that really matter.
Our summit takes place at a critical time for the industry and there is much to discuss. The UK referendum decision to leave the EU has thrown the Unified Patent Court (UPC) preparations into turmoil and has far-reaching implications for life sciences from practical, regulatory and enforcement perspectives.
Key legislative changes around clinical trials, data privacy and trade secrets provide increased opportunities yet simultaneously greater compliance obligations. Ongoing decisions around second medical use patents remain key to planning cross-jurisdictional strategy.
Join colleagues from across Europe to customise your learning, and network in a prestigious and interactive environment.
Get up to speed with the latest legal and regulatory developments on:
- Publishing of clinical trial data
- Second medical use patents
- The data privacy regulation
- The trade secrets directive
Overcome international patentability challenges in:
Benchmark your approach to dealing with:
- Patent protection
- Biosimilars litigation in the US
- ‘Patent trolls’ in Europe
Achieve competitive advantage in preparing for:
- The Nagoya Protocol
- The UPC
- The Transatlantic Trade and Investment Partnership
Understand the latest thinking on:
- Antitrust cases
- The biopatent directive
- Global challenges to patentees and the need for harmonisation
Since the inception of the Life Sciences IP Summit two years ago, C5 has constantly worked hard to produce an innovative and relevant conference which allows our delegates to get the most out of the experience. This year we are taking this one step further by providing four different specialist streams in order to help our delegates tailor their learning to suit their own challenges.
“Join colleagues from across Europe to customise your learning, and network in a prestigious and interactive environment.”
The streams are:
1. Patentability in a global context
2. Key legislative changes in Europe
3. Litigation and patent developments in the emerging markets
4. Can we continue to rely on the conventional system of patent protection?
Best practice strategies in a post-Brexit landscape
The inclusion of our ‘Is There Life (Sciences) After Brexit?’ session aims to provide delegates with the tools and knowledge to prepare for a range of potential implications that could affect the life sciences community after the UK’s surprise vote to leave the EU.
This session will include discussions such as:
- The practical consequences of Brexit
- Extra layer of regulatory requirements in the pharma industry
- Alignment of UK courts and other national patent courts within the EU
- Cross-border injunctions
- The complications of enforcement
- Is Brexit a good thing for the UK and its relationship with supplementary protection certificates?
Don’t miss this opportunity to network with and learn from life sciences IP experts.
You can hear from our prestigious panel of IP industry professionals including:
- Ben Goldacre
- Dorian Immler, chief patent counsel, Bayer Intellectual Property
- Stephen Inglis, director, National Institute for Biological Standards and Control
- Knut Mager, head of data protection, Novartis
- Doris Schernhammer, senior manager for corporate affairs, Eli Lilly
For further information visit the event webpage at www.C5-Online.com/IPSummit2016 or contact Nathan Denham at: n.denham@C5-online.com
Life Sciences IP Summit 2016, Sarah Porch, antitrust, UPC, Brexit, Transatlantic Trade and Investment Partnership, trade secrets directive, clinical data,